Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-28
2006-11-28
Stockton, Laura L. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S325100
Reexamination Certificate
active
07141597
ABSTRACT:
The present invention provides an α-2A/α-1A selective agonist that includes a compound represented by Structure1or a pharmaceutically acceptable salt, ester, amide, sterioisomer or racemic mixture thereof. The present invention further provides a pharmaceutical composition that contains a pharmaceutical carrier and a therapeutically effective amount of an α-2A/α-1A selective agonist that includes a compound represented by Structure1or a pharmaceutically acceptable salt, ester, amide, sterioisomer or racemic mixture thereof.
REFERENCES:
patent: 4798843 (1989-01-01), Kruse
patent: 4868197 (1989-09-01), Schnettler et al.
patent: 0 284 925 (1988-10-01), None
patent: 0 302 603 (1989-02-01), None
patent: 63/150266 (1988-06-01), None
patent: WO 95/29898 (1995-11-01), None
An English translation of JP 63-150266, 1988.
Bylund et al, “IV. International Union of Pharmacology Nomenclature of Adrenoceptors”, Pharmacol. Rev. 46, No. 2:121-136 (1994).
Hein et al, “Review: Neurotransmitter Receptors IV Adrenergic Receptor Signal Transduction and Regulation”, Neuropharmacol. vol. 34, No 4:357-366 (1995).
Calzada et al, “Alpha-Adrenoceptor Subtypes”, Pharmacol. Res. vol. 44, No. 3: 195-208 (2001).
Hein et al. “Gene Substitution/Knockout to Delineate the Role of α2-Adrenoceptor Subtypes in Mediating Central Effects of Catecholaines and Imidazolines”, Ann. NY Acad. Science 881: 265-271 (1999).
Ruffolo (Ed.), α-Adrenoreceptors: Molecular Biology, Biochemistry and Pharmacology, (1991), cover page only.
Shimizu et al, “A Radioisotopic Method for Measuring the Formation of Adenosine 3′, 5′-Cyclic Monophosphate in Incubated Slices of Brain”, J. Neurochem. 16: 1609-1619 (1969).
Jasper et al, “Ligand Efficacy and Potency at Recombinant α2Adrenergic Receptors”, Biochem. Pharmacol. 55: 1035-1043 (1998).
Sullivan et al, Measurement of [Ca2+] Using the Fluorometric Imaging Plate Reader (FLIPR), Methods Mol. Biol. 114: 125-133 (1999).
Kao et al, “Photochemically Generated Cytosolic Calcium Pulses and Their Detection by Fluo-3*”, J. Biol. Chem. 264: 8179-8184 (1989).
Brandish et al., “Scintillation proximity assay of inositol phosphates in cell extracts: High-throughput measurement of G-protein-coupled receptor activation”, Anal. Biochem. 313:311-318 (2003).
Bertrand et al, “The BRET2/Arrestin Assay in Stable Recombinant Cells: A Platform to Screen for Compounds That Interact with G Protein-Coupled Receptors (GPCRS)*”, J. Receptor Signal Transduc. Res. 22: 553-541 (2002).
Neve et al, “Dopamine D2 Receptor Stimulation of Na+/H+Exchange Assessed by Quantification of Extracellular Acidification”, J. Biol. Chem. 267: 25748-25753 (1992).
Lipton et al, “Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders”, New Engl. J. Med. 330: 613-622(1994).
Carelli et al, “Optic nerve degeneration and Mitochondrial dysfunction: genetic and acquired optic neuropathies”, Neurochem. Int. 40: 573-584 (2002).
Olichon et al, “Loss of OPA1 Perturbates the Mitochondrial Inner Membrane Structure and Integrity, Leading to Cytochrome c Release and Apoptosis”, J. Biol. Chem. 278: 7743-7746 (2003).
Block, “Attention-Deficit Disorder, A Paradigm for Psychotropic Medication Intervention in Pediatrics”, Pediatr. Clin. North Am. 45: 1053-1083 (1998).
Pary et al, “Attention Deficit Disorder in Adults”, Ann. Clin. Psychiatry 14: 105-111 (2002).
Cordi et al, “Efficient Synthesis of (S)-4(5)-[1-(2,3-Dimethylphenyl)Ethyl]Imidazole Tartrate, The Potent α2Adrenoceptor Agonist Dexmedetomidine”, Synth. Comm. 26: 1585 (1996).
Ciufolini et al, “The Total Synthesis of Cystodytins”, J. Amer. Chem. Soc. 113: 8016-8024 (1991).
Horne et al, “A Two-Step Synthesis of Imidazoles from Aldehydes Via 4-Tosyloxazolines”, Heterocycles 39: 139-153 (1994).
Hylden et al, “Intrathecal Morphine in Mice: A New Technique ”, Eur. J. Pharmacol. 67: 313-316 (1980).
Minami et al, “Allodynia evoked by intrathecal administration of prostaglandin E2to conscious mice”, Pain 57: 217-223 (1994).
Chow Ken
Donello John E.
Gil Daniel W.
Heidelbaugh Todd M.
Allergan Inc.
Baran Robert J.
Johnson Brent A.
Stockton Laura L.
Voet Martin A.
LandOfFree
Nonsedating α-2 agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nonsedating α-2 agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nonsedating α-2 agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3636325